CPA
RVMD icon

Capital Performance Advisors’s Revolution Medicines RVMD Stock Holding History

Capital Performance Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16
Closed -$726 – 2171
2024
Q3 		$726 Buy
+16
New +$697 ﹤0.01% 2076

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Performance Advisors's RVMD Position: Q4 2024 in Review

Capital Performance Advisors sold out of Revolution Medicines (RVMD) in Q4 2024, closing a stake of 16 shares — an estimated $726 sold.

Capital Performance Advisors first reported a position in RVMD in Q3 2024 and held it in 1 quarter. The position peaked at $726 in Q3 2024. 281 funds tracked by Wall St. Rank hold RVMD as of Q4 2024.

  • Capital Performance Advisors reported no remaining Revolution Medicines position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 16 Revolution Medicines shares in Q4 2024, an estimated $726.
  • Capital Performance Advisors first reported a position in Revolution Medicines in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Revolution Medicines position peaked at $726 in Q3 2024.
  • 281 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.